Actively Recruiting

Age: 18Years +
All Genders
NCT06229860

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Led by University of California, Irvine · Updated on 2026-03-10

75

Participants Needed

1

Research Sites

148 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

CONDITIONS

Official Title

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Diagnosed with chronic myeloid leukemia (CML) in the chronic phase
  • Currently treated with imatinib, dasatinib, bosutinib, or nilotinib
  • Patient at UCI Chao Family Comprehensive Cancer Center or member of CML Buster Foundation support group
  • Do not meet any exclusion criteria
Not Eligible

You will not qualify if you...

  • Unable to read and speak English
  • Impaired decisional capacity to consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chao Family Comprehensive Cancer Center University of California, Irvine

Orange, California, United States, 92868

Actively Recruiting

Loading map...

Research Team

C

Chao Family Comprehensive Cancer Center University of California, Irvine

CONTACT

U

University of California Irvine Medical

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here